Statements (52)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:administered_by |
oral tablet
|
| gptkbp:approves |
gptkb:1978
gptkb:Canada gptkb:European_Union gptkb:United_States |
| gptkbp:available_on |
generic medication
|
| gptkbp:brand |
gptkb:Dolobid
|
| gptkbp:casnumber |
22494-42-4
|
| gptkbp:chemical_formula |
C13 H10 O3 S
|
| gptkbp:clinical_trial |
pain management studies
osteoarthritis studies post-operative pain studies rheumatoid arthritis studies |
| gptkbp:contraindication |
peptic ulcer disease
severe renal impairment hypersensitivity to salicylates |
| gptkbp:developed_by |
gptkb:Eli_Lilly_and_Company
|
| gptkbp:dosage_form |
1000 mg daily
500 mg twice daily |
| gptkbp:duration |
long-term use
short-term use |
| gptkbp:formulation |
gptkb:tablet
suspension |
| https://www.w3.org/2000/01/rdf-schema#label |
diflunisal
|
| gptkbp:interacts_with |
gptkb:methotrexate
gptkb:warfarin other NSAIDs |
| gptkbp:marketed_as |
anti-inflammatory agent
analgesic agent antipyretic agent |
| gptkbp:mechanism_of_action |
inhibition of cyclooxygenase
|
| gptkbp:pharmacokinetics |
excreted in urine
metabolized in the liver highly protein-bound |
| gptkbp:related_to |
salicylic acid
aspirin |
| gptkbp:research_areas |
chronic pain management
post-surgical recovery inflammatory diseases |
| gptkbp:safety_features |
generally well tolerated
risk of cardiovascular events risk of gastrointestinal bleeding risk of renal impairment |
| gptkbp:side_effect |
dizziness
headache rash gastrointestinal upset |
| gptkbp:used_for |
pain relief
inflammation reduction |
| gptkbp:bfsParent |
gptkb:Transthyretin_amyloidosis
|
| gptkbp:bfsLayer |
6
|